Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03838510 · ClinicalTrials.gov registry record · NA

Repeated-dose Behavioral Intervention to Reduce Opioid Overdose

A NA study of Opioid-Related Disorders and Drug Overdose, sponsored by San Francisco Department of Public Health.

Completed
Registry status
NA
Development phase
268
Enrollment target
2
Study locations

NCT03838510 is a NA study of Opioid-Related Disorders and Drug Overdose that has completed, run by San Francisco Department of Public Health. The registered enrollment target is 268 participants, below the 341-participant average among 47 other Opioid-Related Disorders trials with a reported enrollment target (21% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03838510, a NA study of Opioid-Related Disorders and Drug Overdose, has completed, sponsored by San Francisco Department of Public Health.

COMPLETED
Registry status
NA
Development phase
268 participants
Enrollment target
2
Study locations

Study Summary

REBOOT is a randomized trial of a repeated-dose brief intervention to reduce overdose and risk behaviors among naloxone recipients with opioid use disorder. It includes an established overdose education curriculum within an Informational-Motivation-Behavior (IMB) model. This study will test the efficacy of REBOOT vs attention-control.

Interventions

  • BEHAVIORAL REBOOT

Study Locations (2)

California

  • San Francisco Department of Public Health - San Francisco

Massachusetts

  • Boston Medical Center - Boston

Trial Details

FieldValue
Enrollment Target 268 participants
Start Date 2019-04-22
Est. Completion 2023-12-12
Phase NA

What the Registry Record Tells You About NCT03838510

The ClinicalTrials.gov registry entry for NCT03838510 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 268 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 341-participant average among 47 other Opioid-Related Disorders trials with a reported enrollment target (21% lower). The listed sponsor is San Francisco Department of Public Health, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Opioid-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which REBOOT is the first listed.

NCT03838510 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03838510 about?

NCT03838510 is a clinical study titled "Repeated-dose Behavioral Intervention to Reduce Opioid Overdose". REBOOT is a randomized trial of a repeated-dose brief intervention to reduce overdose and risk behaviors among naloxone recipients with opioid use disorder. It includes an established overdose education curriculum within an Informational-Motivation-Behavior (IMB) model. This study will test the effi...

What is the current status of trial NCT03838510?

This trial is currently completed. It is a NA study. The enrollment target is 268 participants. The study started on 2019-04-22. Estimated completion is 2023-12-12.

What conditions does trial NCT03838510 study?

This clinical trial studies the following conditions: Opioid-Related Disorders, Drug Overdose.

What interventions are being tested in trial NCT03838510?

The interventions under investigation include: REBOOT (BEHAVIORAL).

Who is sponsoring clinical trial NCT03838510?

This trial is sponsored by San Francisco Department of Public Health, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03838510 being conducted?

This trial has 2 study locations across California, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Opioid-Related Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.